Monoclonal antibody
Depatuxizumab mafodotin Type Whole antibody Source Chimeric/humanized hybrid (mouse/human) Target EGFR Other names ABT-414 ATC code CAS Number ChemSpider UNII KEGG Formula C 6624 H 10228 N 1728 O 2052 S 42 Molar mass 148251 .25 g·mol−1
Depatuxizumab mafodotin (INN; development code ABT-414 ) is an antibody-drug conjugate designed for the treatment of cancer.[1] [2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.[3] [4]
This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.[5]
In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.[6] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.[7] Phase I results were presented at ASCO in 2016.[7]
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association .
^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF) . WHO Drug Information . 30 (2).
^ "Antibody-drug conjugates in the spotlight - The Antibody Society". antibodysociety.org . 14 October 2016.
^ Nagayama A, Ellisen LW, Chabner B, Bardia A (December 2017). "Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments". Targeted Oncology . 12 (6): 719–739. doi:10.1007/s11523-017-0535-0. PMID 29116596. S2CID 1012740.
^ "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019". abbvie.com . Retrieved 20 May 2019 .
^ "Depatuxizumab mafodotin". en.pharmacodia.com .
^ a b "Depatuxizumab mafodotin - AbbVie - AdisInsight". adisinsight.springer.com .
Last Update: 2023-04-03T04:20:27Z
Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR...
Word Count : 261
Last Update: 2024-04-07T05:36:09Z
Veltuzumab§ Vorsetuzumab mafodotin § Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin † Duvortuxizumab Ontuxizumab§...
Word Count : 1722
Last Update: 2024-04-27T02:56:13Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 524
Last Update: 2024-03-21T22:16:34Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 3413
Last Update: 2024-03-20T19:54:30Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 2542
Last Update: 2024-03-31T19:14:09Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1131
Last Update: 2024-04-07T05:47:37Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1489
Last Update: 2024-03-26T05:49:17Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1645
Last Update: 2024-02-26T05:55:48Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 3069
Last Update: 2024-04-10T06:21:42Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 3010
Last Update: 2024-04-17T23:02:25Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1649
Last Update: 2024-02-28T03:22:37Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1735
Last Update: 2024-04-26T20:10:05Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 3123
Last Update: 2024-05-16T06:55:25Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 15756
Last Update: 2022-06-16T04:46:03Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1081
Last Update: 2024-03-10T04:01:55Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 7427
Last Update: 2024-01-01T05:15:47Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 596
Last Update: 2024-04-10T06:00:44Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 934
Last Update: 2024-04-13T05:44:24Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 3128
Last Update: 2024-01-17T14:08:35Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 5251
Last Update: 2024-03-10T03:07:31Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 914
Last Update: 2024-04-20T13:03:38Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 991
Last Update: 2024-04-24T03:21:31Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1122
Last Update: 2024-04-26T23:53:23Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 2786
Last Update: 2024-01-06T04:08:10Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 1784
Last Update: 2024-04-17T06:09:06Z
Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab...
Word Count : 7144